Related Experiment Video
Updated: Jun 19, 2026
08:25
Visualization of Streptococcus pneumoniae within Cardiac Microlesions and Subsequent Cardiac Remodeling
Published on: April 7, 2015
MOUSE-PROTECTIVE TITERS OF SERA OF VOLUNTEERS FOLLOWING INJECTION OF PNEUMOCOCCI OR THEIR TYPE-SPECIFIC
A W Walter1, E L Schenkein, W D Sutliff
1Bureau of Laboratories of the Department of Health of the City of New York, New York.
The Journal of Experimental Medicine
|October 30, 2009
Summary
Human sera immunized with pneumococci showed type-specific antibodies. The ratio of protective units to antibody levels varied, being lower in less potent human sera, indicating differences in antibody efficacy.
Area of Science:
- Immunology
- Microbiology
- Vaccinology
Background:
- Pneumococcal infections pose a significant global health burden.
- Effective vaccines rely on eliciting robust and protective antibody responses.
- Assessing antibody potency is crucial for vaccine efficacy evaluation.
Purpose of the Study:
- To determine the presence and specificity of antibodies in human sera after immunization with pneumococci or their polysaccharides.
- To compare the ratio of protective antibody units to antibody nitrogen in human and animal sera of varying potencies.
Main Methods:
- Human sera from immunized subjects were analyzed.
- Antibody presence and specificity were assessed using mouse protection tests.
- Specifically precipitable nitrogen was quantified to measure antibody levels.
Main Results:
- Type-specific antibodies against pneumococci were detected in human sera post-immunization.
- Both mouse protection tests and nitrogen determinations confirmed antibody presence.
- A lower ratio of mouse-protective units to antibody nitrogen was observed in low-potency human sera compared to potent human or animal sera.
Conclusions:
- Human immunization with pneumococci or polysaccharides successfully generates type-specific antibodies.
- Antibody potency, as indicated by the protective unit to nitrogen ratio, can vary significantly.
- Further research into factors influencing antibody efficacy is warranted for improved vaccine development.
